BISPECIFIC T-CELL ENGAGING ANTIBODIES FOR CANCER THERAPY
- At: 2015 FIP Congress in Düsseldorf (Germany)
- Type: Presentation
- By: WOLF, Andreas (Amgen Research Munich, München, Germany)
- Co-author(s): Andreas Wolf
BiTE™ antibodies are single-chain bispecific antibody constructs with specificity for CD3 on T cells and a selected surface antigen on target cells. By transiently bridging T cells and cancer cells, BiTE™ antibodies are capable to fully activate T cells and to mount a polyclonal T cell response that is no longer restricted by T cell receptor.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.